Physician profile
Stephen B Lamb
NPI 1609086057
$5,323.43
in general payments reported to CMS, 2019-2025
16 companies · $607 in 2025
The $607 reported for 2025 was more than what 81% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,532 · 2020: $51.23 · 2022: $253 · 2023: $493 · 2024: $387 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,077.71 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.58 | 2022-2025 | Caplyta |
| Alkermes, INC. | $380.22 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $301.92 | 2019-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $301.67 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $163.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $137.22 | 2019 | |
| Axsome Therapeutics, INC. | $93.98 | 2023-2025 | Auvelity |
| Mdd US Operations, LLC | $84.36 | 2019-2020 | |
| Allergan, INC. | $37.89 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $32.57 | 2023 | Quviviq |
| Orexo US, INC. | $28.14 | 2019 | |
| Abbvie INC. | $23.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.28 | 2023 | Trintellix |
| Neuronetics, INC. | $12.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.